Piper Sandler Begins Coverage on Upstream Bio (NASDAQ:UPB)

Piper Sandler began coverage on shares of Upstream Bio (NASDAQ:UPB) in a research report released on Tuesday morning, MarketBeat.com reports. The firm issued an overweight rating and a $75.00 target price on the stock.

Other research analysts also recently issued research reports about the stock. JPMorgan Chase & Co. assumed coverage on shares of Upstream Bio in a research note on Tuesday. They issued an “overweight” rating and a $38.00 target price for the company. TD Cowen assumed coverage on Upstream Bio in a report on Tuesday. They issued a “buy” rating for the company. Finally, William Blair assumed coverage on shares of Upstream Bio in a research note on Tuesday. They set an “outperform” rating for the company.

Upstream Bio Stock Performance

Upstream Bio stock opened at $27.02 on Tuesday. Upstream Bio has a fifty-two week low of $20.74 and a fifty-two week high of $29.46.

Insider Buying and Selling at Upstream Bio

In other Upstream Bio news, major shareholder Ai Upstream Llc bought 1,175,000 shares of the business’s stock in a transaction dated Tuesday, October 15th. The shares were acquired at an average price of $17.00 per share, with a total value of $19,975,000.00. Following the purchase, the insider now owns 1,175,000 shares in the company, valued at approximately $19,975,000. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In related news, Director Erez Chimovits bought 825,000 shares of the firm’s stock in a transaction dated Tuesday, October 15th. The stock was bought at an average price of $17.00 per share, with a total value of $14,025,000.00. Following the completion of the transaction, the director now directly owns 4,554,873 shares of the company’s stock, valued at approximately $77,432,841. This represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder Ai Upstream Llc bought 1,175,000 shares of the company’s stock in a transaction that occurred on Tuesday, October 15th. The shares were bought at an average price of $17.00 per share, for a total transaction of $19,975,000.00. Following the completion of the acquisition, the insider now owns 1,175,000 shares in the company, valued at approximately $19,975,000. The disclosure for this purchase can be found here.

Upstream Bio Company Profile

Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.